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Abstract: Background. Late occurrence of cytomegalovirus (CMV)
infection remains a concern in CMV-seronegative kidney and/or
pancreas transplant recipients of CMV-seropositive organs (donor
positive/recipient negative, D 1 /R ) despite the use of prophylaxis.
We investigated the impact of various antibody induction regimens on
CMV infection in this group of patients.
Methods. A total of 254 consecutive D 1 /R kidney and/or pancreas
transplant patients were studied.The induction agents rabbit anti-
thymocyte globulin (rATG) or basiliximab were used according to the
center practice. All patients received prophylaxis with valganciclovir
(VGCV) for either 3 or 6 months.The occurrence of CMV infection was
con¢rmed by positive DNAviremia. Multivariate Cox regression
analyses were performed to determine risk factors for CMV infection.
Results.The cumulative incidence of CMV infection was 58, 112, and 59
cases per 1000 patient-years for patients who received no antibody
induction, induction with rATG, or basiliximab induction, respectively
(P5 0.02).The use of rATG but not basiliximab was associated with an
increased risk for CMV infection (adjusted hazard ratio [AHR] 2.13,
95% con¢dence interval [CI] 1.24^3.54, P 5 0.006). Acute rejection and
its treatment with rATG were not associated with an increased risk for
CMV infectionwhen an additional course of VGCVwas given following
the treatment. Longer duration of prophylaxis was associated with a
reduced risk for CMV infection (AHR 0.54, 95% CI 0.33^0.87, P 5 0.011).
Conclusions. Induction with rATG is associated with increased risk of



























































































































Late occurrence of cytomegalovirus (CMV) infection
remains one of the most common opportunistic infections
in solid organ transplantation (SOT) despite availability of
speci¢c and e⁄cacious antiviral drugs (1, 2). In addition to
mismatched donor and recipient CMVserology (donor pos-
itive/recipient negative, D 1 /R ), the enhanced intensity
of immunosuppression, as with the use of anti-lymphocyte
antibodies, is the most important risk factor (3, 4). CMV
infection causes signi¢cant morbidity, increases mortality,
and is associatedwith inferior transplant outcomes, partic-
ularly in kidney transplantation (5^9).
The use of rabbit anti-thymocyte globulin (rATG) or anti-
interleukin (IL)-2 receptor antibodies (basiliximab and
daclizumab) has increased substantially among SOT
patients in the recent era. The use of these agents has re-
sulted in reduced incidence of acute rejection. On the other
hand, the use of rATG causes profound T lymphocyte
depletion and has been shown to increase the risk of
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infections, particularly CMV infection (4, 10, 11). The e¡ect
of anti-IL2 receptor antibodies on the incidence of CMV in-
fection is less clear (3, 11^14). In all clinical trials comparing
rATG and anti-IL-2 receptor antibodies, the risk of CMV in-
fection, not limited to D 1 /R patients, appears similar in
some but di¡erent in other studies, often without a uni¢ed
prophylaxis approach (15^17 ).
The current study is based on a single-center experience
involving D 1 /R kidney and/or pancreas transplant
patients treated with universal valganciclovir (VGCV) pro-
phylaxis for 3^6 months after transplantation. This retro-
spective study aims to compare the risk of CMV infection
among patients who received no induction, induction with
rATG, or induction with basiliximab.
Materials andmethods
All D 1 /R kidney and/or pancreas transplant recipients
from March 1, 2002 to December 31, 2007 who survived
through at least the period of prophylaxis with a function-
ing graft were included. All patients received prophylaxis
withVGCV 450 mg daily, a dose determined by the institu-
tional protocol and adjusted according to transplant renal
function, for 3 months (March 2002 to September 2005) or
6 months (October 2005 to December 2007 ) after transplan-
tation, and were followed up to the time of graft loss, death,
or till April 30, 2009. The study was approved by the insti-
tutional review board.
Immunosuppression regimens, including induction
and maintenance, were provided according to the institu-
tional protocols. For induction regimen, rATG (Thymo-
globulins, Genzyme, Cambridge, Massachusetts, USA)
or basiliximab (Simulects, Novartis, East Hanover,
New Jersey, USA) were utilized where dictated by the
speci¢c center protocols. More speci¢cally, kidney trans-
plant patients with panel reactive antibodies titer  20,
and/or African^American racial identi¢cation were gen-
erally given rATG, whereas patients with delayed or slow
graft function and panel reactive antibodies between
0 and 19 were given basiliximab. Pancreas transplant re-
cipients were always given antibody induction: basil-
iximab in the early period and rATG in more recent era.
For maintenance immunosuppression, a triple drug regi-
men, which consisted of a calcineurin inhibitor (CNI)
(cyclosporine or tacrolimus), an anti-proliferative agent
(mycophenolate mofetil, mammalian target of rapamycin
drugs ^ sirolimus/everolimus, and others), and prednis-
one was usually used.Target trough levels for cyclospor-
ine and tacrolimus were 150^300 and 5^15 ng/mL,
respectively, during the ¢rst 3 months. Subsequently,
cyclosporine and tacrolimus trough levels were main-
tained at 100^150 and 5^8 ng/mL, respectively. Predni-
sone was tapered to 10 mg/day at about 8 weeks post
transplant and remained at 5^10 mg daily thereafter over
the study period.
The primary endpoint was the incidence of CMV infec-
tion diagnosed by positive DNA viremia determination
using polymerase chain reaction (PCR) technique,
regardless of the presence of symptoms during the entire
duration of follow-up.W|th the exception of one-time pro-
tocol-driven CMV/PCR determination at the end of pro-
phylaxis period in a few patients transplanted in the
later era (October 2005 to December 2007 ), the greater
majority of CMV/PCR testing was requested based upon
clinical suspicion by transplant physicians.The test was
performed on the platform of COBAS Amplicor instru-
ment with all reagents purchased from the Roche Diag-
nostics (Indianapolis, Indiana, USA). The most common
clinical suspicions for ordering such determination were
gastroenteric symptoms, viral-like symptoms, and/or
leukopenia, particularly neutropenia. In patients with
symptomatic infection, the tissue diagnosis to document
the presence of tissue invasion was obtained in some
patients on a case-by-case basis as determined by physi-
cians. Patients with a diagnosis of CMV infection, with
or without symptoms, were treated with an additional
course of either intravenous (IV) ganciclovir or oral
VGCV and temporary discontinuation of anti-prolifera-
tive agents for up to 2^3 weeks (induction therapy
phase).
Episodes of acute rejection were documented through
clinically indicated biopsy and classi¢ed according to
Ban¡ criteria (18, 19). The treatment of acute rejection fol-
lowed a center-speci¢ed protocol: acute rejection of mild de-
gree (Ban¡ 1a or lower) was treated with a 3 -day IV steroid
bolus, and acute rejection of moderate-to-severe degree
(Ban¡ 1b or higher) was treated with a 7^10 -day course of
rATG. All patients treatedwith rATGwere givenVGCVpro-
phylaxis, 450 mg daily and adjusted for renal function, for
an additional 3 months.
Analysis of variance and w2-tests were used to compare
continuous and categorical variables, respectively, for
baseline demographic and clinical characteristics between
patients from various groups according to the type of in-
duction regimen they received at the time of transplant.
A Poissonmodelwas utilized to compare the cumulative in-
cidence of CMV infection among the groups. Relative risk
for CMV infection was calculated using w2-test as well.The
Kaplan^Meier method was used to estimate the incidences
of CMV infection strati¢ed by induction agents used.
Multivariate Cox proportional hazard regression analysis
was used to identify the risk factors for CMV infection. Sta-
tistical signi¢cance was set at a P value of  0.05.
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Results
A total of 254 consecutive CMV D 1 /R kidney and/or
pancreas transplant recipients were included in this study.
The median follow-up was 1236 days from the time of
transplant with range between 164 and 2586 days. Among
them, 96 patients received no induction, and 114 and 44
patients received induction with rATG or basiliximab,
respectively. Demographic and baseline clinical character-
istics of patients from the 3 groups are presented inTable 1.
Patients were comparable with respect to age, gender,
hepatitis C virus serology, the use of expanded criteria do-
nor kidney, incidence of acute rejection, and baseline renal
function. However, the racial composition, the use of living
donors, the number of pancreas transplants, the number of
Demographic and baseline characteristics
Non-induction rATG Basiliximab
PN596 N 5114 N5 44
Age (years, mean  SD) 45.9  12.5 43.0  12.3 47.6  9.7 0.06
Gender (male, %) 68 (70.8) 77 (67.5) 29 (65.9) 0.81
Race (AA, %) 2 (2.1) 35 (30.7) 0 (0) o0.001
Hepatitis C virus positivity (%) 3 (3.1) 5 (4.4) 1 (2.3) 0.62
Delayed graft function (%) 1 (1.1) 16 (14.0) 7 (15.9) 0.002
Acute rejection (%) 0.29
Mild1 16 (16.7) 14 (12.3) 5 (11.4)
Moderate/severe2 12 (12.5) 18 (15.8) 2 (4.5)
Calcineurin inhibitors (%) o0.001
CsA 92 (95.8) 87 (76.3) 27 (61.4)
Tac 4 (4.2) 27 (23.7) 17 (38.6)
Anti-proliferative agents (%) 0.05
MMF 85 (88.5) 105 (92.1) 41 (93.2)
mTor 4 (4.2) 8 (7.0) 3 (6.8)
Others 7 (7.3) 1 (0.9) 0 (0.0)
Extended criteria donor (%) 12 (12.5) 15 (13.2) 6 (13.6) 0.98
Living donor (%) 54 (56.3) 52 (45.6) 5 (11.4) o0.001
Pancreas transplant (%) 0 (0) 19 (16.7) 8 (18.2) o0.001
First transplant (%) 89 (92.7) 81 (71.1) 38 (86.4) 0.001
Renal diagnosis (%) 0.002
APKD 12 (12.5) 7 (6.1) 6 (13.6)
DM 29 (30.2) 42 (36.8) 27 (61.4)
GN 28 (29.1) 27 (23.7) 4 (9.1)
HTN 6 (6.3) 16 (14.1) 0 (0.0)
Others 21 (21.9) 22 (19.3) 7 (15.9)
Duration of prophylaxis (%) 0.01
3 months 61 (63.5) 49 (43.0) 25 (56.8)
6 months 35 (36.5) 65 (57.0) 19 (43.2)
Serum creatinine (mg/dL, mean  SD) 1.2  0.3 1.3  0.5 1.2  0.3 0.12
Follow-up (days, mean  SD) 1450  600 1229  590 1401  654 0.02
1Ban¡ 1a or lower.
2Ban¡ 1b or greater.
rATG, rabbit anti-thymocyte globulin; SD, standard deviation; Basiliximab, anti-IL2 receptor antibody; AA, African^American; CsA, cyclosporine A;Tac,
tacrolimus; MMF, mycophenolate moftile; mTor, mammalian target of rapamycin; APKD, adult polycystic kidney disease; DM, diabetes mellitus; GN,
glomerulonephritis; HTN, hypertension.
Table1
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¢rst transplants, the cases of delayed graft function, and
the use of various CNIs and anti-proliferative agents were
signi¢cantly di¡erent among the groups. The overwhelm-
ing representation of African^American patients in
the rATG group and pancreas transplant patients in the
rATG and/or basiliximab groups re£ects the institutional
protocols.
During the study period, 75 cases of CMV infection
(29.5%) were documented by positive CMV viremia
(Fig. 1A). Five of themwere diagnosed through the one-time
protocol-driven CMV/PCRdetermination.The median time
to CMV infectionwas 208 days from the time of transplant,
with a range from 101 to 2025 days post transplant. Follow-
ing the current recommendation guideline, 49 patients had
probable or con¢rmed CMVgastroenteric disease (65.3%)
with or without signs of hepatitis and pancreatitis, 11 pa-
tients had CMV syndrome (14.7%), 2 patients had CMV
pneumonitis (2.6%), and 1 patient each had nephritis
(1.3%) and retinitis (1.3%) (20). Eleven patients (14.7%)
were without symptoms or signs suggestive of CMV dis-
ease. The tissue invasion was documented in a small frac-
tion of patients by endoscopy, broncoscopy, renal biopsy,
etc. No case of CMV infection occurred during the prophy-
laxis period. No case of CMV infection with negative
viremia occurred in this cohort.
The cumulative incidence of CMV infection was 57, 112,
and 59 cases per 1000 patient-years follow-up among
patients receiving no induction, or induction with rATG or
basiliximab, respectively (P5 0.02). Table 2 shows the pro-
portion of overall CMV infection between the 3 groups as
well as the relative risk as determined by univariate analy-
sis. Induction with rATG was associated with a 51%
increase in the risk for CMV infection compared with no in-
duction (risk ratio [RR] 1.51, 95% con¢dence interval [CI]
1.04^2.19, P5 0.02), whereas induction using basiliximab
did not appear to a¡ect the risk of CMV infection (RR 1.00,
95%CI 0.76^1.30, P5 0.98). Kaplan^Meier survival analysis
demonstrated the di¡erence in the incidence of CMV infec-
tion among patients receiving no induction, induction with
rATG, or basiliximab induction (log-rank, P5 0.027 )
(Fig. 1B).
During the study period, 67 patients experienced 85 epi-
sodes of acute rejection. Eighteen of 75 patients with CMV
infection had a total of 19 episodes of acute rejection,
whereas 49 out of 179 patients without CMV infection expe-
rienced 66 episodes of acute rejection. No signi¢cant di¡er-
ence was seen in the incidence of acute rejection between
the 2 groups (P5 0.58 for comparison on the number of
patients experiencing acute rejection, and P5 0.12 for com-
parison on episodes of acute rejection, respectively). Of 18
patientswith CMV infectionwho had experienced episodes
of acute rejection, 11 patients had 11 episodes of acute rejec-
tion before the episode of CMV infection (5 with mild and
6 with moderate-to-severe degree of acute rejection); and
7 patients had 8 episodes of acute rejection following CMV
infection (5 with mild and 2 with moderate-to-severe degree
of acute rejection).
To determine the impact of acute rejection on the future
risk of developing CMV infection, we excluded episodes of
acute rejection that occurred after CMV infection among
patients with a diagnosis of CMV infection. By univariate
analysis, the presence of acute rejection was associated
with a lower risk of CMV infection (RR 0.82, 95% CI 0.70^
0.96, P5 0.03).Whenwe further categorized acute rejection
Fig. 1. (A) Overall cytomegalovirus (CMV) infection free survival, and
(B) CMV infection free survival by induction regimens.







risk 95% CI P
None (N 596) 22 (22.9) Ref. N/A N/A
rATG (N 5114) 43 (37.7) 1.51 1.04, 2.19 0.02
Basiliximab (N 5 44) 10 (22.7) 1.00 0.76, 1.30 0.98
CI, con¢dence interval; rATG, rabbit anti-thymocyte globulin; Basiliximab,
anti-IL2 receptor antibody.
Table 2
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according to its histological severity, Ban¡ 1a or lower treat-
ed with high-dose IV steroid bolus, and Ban¡ 1b or higher
treated with a course of rATG, this lower risk of developing
CMV infection was no longer observed (data not shown).
Finally, we performed multivariate Cox proportional
hazard regression analysis.We included all baseline covari-
ates that showed signi¢cant di¡erence in distribution by
univariate analyses. The ¢nal model thus included the fol-
lowing covariates: age, race, the type of induction agents,
acute rejection before CMV infection as a time-dependent
covariate, underlying kidney disease diagnosis, the type
of transplant (living vs. deceased and kidney vs. pancreas),
the number of transplants, the presence of delayed graft
function, the use of di¡erent CNIs and anti-proliferative
agents, and the duration of prophylaxis. The use of rATG
but not basiliximab was associated with a statistically sig-
ni¢cant increase in the risk for CMV infection (adjusted
hazard ratio [AHR] 2.13, 95% CI 1.24^3.54, P5 0.006). Epi-
sodes of acute rejection, treated with high-dose IV steroids
and/or rATG, were not associated with an increased risk of
developing CMV infection during subsequent follow-up
(AHR 0.70, 95% CI 0.37^1.33, P5 0.27 ). Longer duration of
prophylaxis withVGCVappeared associated with a signi¢-
cant reduction in the risk for late CMV infection (AHR 0.54,
95% CI 0.33^0.87, P5 0.011) (Table 3).
Discussion
D 1 /R CMV serology mismatch and intensity of
immunosuppression, particularly with the use of anti-lym-
phocyte antibody for induction or treatment of acute rejec-
tion, are the 2 most important risk factors for the
development of CMV infection despite the routine use of
universal prophylaxis (2^4, 11, 21). Our study here shows
that the choice of induction agents impacts di¡erently the
risk of late CMV infection in D 1 /R kidney and/or pan-
creas transplant recipients. In particular, the use of rATG, a
T-cell depleting antibody, for inductionwas associatedwith
a signi¢cant increase in the risk of CMV infection during a
median follow-up of nearly 3.5 years. On the other hand, the
use of basiliximab, a non-T-cell depleting antibody, did not
appear to in£uence the risk of CMV infection. Interestingly,
the use of rATG for treatment of acute rejection was not as-
sociated with increased risk of CMV infection when an ad-
ditional course of VGCVwas provided.
Two approaches, namely universal prophylaxis and pre-
emptive therapy, have been variably advocated and found
to be of similar e⁄cacy in preventing symptomatic CMV
infection in SOT patients across various donor and recipi-
ent CMV serology combinations. However, only universal
prophylaxis has resulted in reduced CMVorgan disease in
D 1 /R SOTpatients (22^24). Nonetheless, the late occur-
rence of CMV infection remains a serious problem among
this group of patients with incidence varying from 30% to
as high as 48% (2, 25). Our ¢ndings of 29.5% incidence rate
are in line with those ¢ndings. Previous studies comparing
rATG and anti-IL2 receptor antibodies have mostly focused
on their clinical e⁄cacy with CMV infection often as sec-
ondary endpoint and not limited only to D 1 /R recipi-
ents. Furthermore, antiviral prophylaxis was not
universally applied in some of these studies. Thus the
results often di¡er from study to study (15, 16, 26, 27 ).
Lebranchu et al. (15) showed that, in the absence of prophy-
laxis, the use of rATG was associated with higher risk for
CMV infection than the use of basiliximab. On the other
hand, Brennan et al. (16) showed opposite ¢ndings with ba-
siliximab induced patients having more CMV infection
when universal prophylaxis was provided. One of the pos-
sible explanations for their ¢ndings was the higher inci-
dence of acute rejection in basiliximab-treated patients
that required subsequent use of T-cell depleting antibodies,
but no information was available regarding whether addi-
tional prophylaxis was given.Two other studies showed no
di¡erence in the risk of CMV infection between patients gi-
ven rATG or basiliximab and daclizumab, although the
time to the onset of CMV infection appeared shorter in pa-
tientswho received rATG (26, 27 ). All these studies included
patients of all donor and recipient CMV serology combina-
tions, and only limited numbers of D 1 /R patients.
The possible explanation of our observation rests on the
fact that rATG and basiliximab have di¡erent e¡ects on im-
mune competent cells involved in developing anti-infec-
tious response. While rATG is a polyclonal antibody
Clinical predictors of cytomegalovirus (CMV) infection bymultivariate Cox
proportional hazard regression analysis
Variables
Hazard
ratio 95% CI P
Induction regimens (ref5 no induction)
rATG 2.13 1.24, 3.54 0.006
Basiliximab 1.01 0.48, 2.14 0.97
Prophylaxis regimens
6 months vs. 3 months 0.54 0.33, 0.87 0.011
Acute rejection before CMV infection
(ref5 no rejection)
0.70 0.37, 1.33 0.27
Mild1 0.69 0.28, 1.72 0.42
Moderate/severe2 0.73 0.31, 1.69 0.45
1Ban¡ 1a or lower.
2Ban¡ 1b or greater.
CI, con¢dence interval; rATG, rabbit anti-thymocyte globulin; Basiliximab,
anti-IL2 receptor antibody.
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causing both complement-dependent and -independent
lysis of T lymphocytes (CD4 and CD8), B lymphocytes,
and antigen presenting cells, basiliximab is a monoclonal
antibody that binds to CD25 expressed only in activated T
and B lymphocytes without causing generalized lympho-
cyte depletion (10, 28^30). It has been well documented that
speci¢c anti-CMV immune response is a primarily T lym-
phocyte-dependent process (31, 32).The depletion of T lym-
phocyte populationwill thus result in absence of anti-CMV
response and lack of CMVclearance (33).
Acute rejection is a known risk factor for CMV disease
among SOT patients (21, 34, 35). Treatment of acute rejec-
tion with enhanced immunosuppression, using either high
doses of steroids or anti-lymphocytic agents, likely contrib-
utes to such enhanced risk. Most studies have not investi-
gated the impact of di¡erent treatment modalities for acute
rejection on the risk of subsequent CMV infection; and/or
did not provide information about whether additional
CMV prophylaxis following anti-rejection treatment was
provided. In fact, one recent study by Arthurs et al. (9)
showed that when prophylaxis was given after anti-rejec-
tion treatment, a lower risk of delayed-onset CMV disease
was observed.Thus, the results of our study are consistent
with their ¢ndings and provide additional evidence that
acute rejection and its treatment do not increase the risk of
subsequent CMV infection in D 1 /R kidney and/or pan-
creas transplant patients when universal prophylaxis is
provided at the time of transplant, and an additional course
of prophylaxis is given after the use of T-cell depleting
antibody for acute rejection. It is possible that increased
immune response in the setting of acute rejection, in addi-
tion to the post-antirejection prophylaxis, could have con-
tributed to the observed lower risk of CMV infection.
The major strengths of our study rely on the sample size,
which to the best of our knowledge, is one of the largest
involving only D 1 /R kidney and/or pancreas trans-
plant recipients, the number of cases with CMV infection,
and long duration of follow-up with only 3 patients lost to
follow-up 4345 days after transplant. In addition, in our
study the diagnosis of CMV infection was uniformly made
through the determination of DNAviremia, and universal
prophylaxis was provided to all study subjects. We were
therefore able to directly compare no induction versus 2
di¡erent but commonly used induction agents and to as-
sess the risk of CMV infection. Furthermore, we had de-
tailed information on the episodes of acute rejection and
its treatment and were able to estimate the impact
of acute rejection and its treatment on the risk of CMV
infection.
Our study su¡ers several limitations. First, the 3 groups
of patients di¡ered signi¢cantly in several important base-
line characteristics such as racial composition, donor
source, type of transplants, presence of delayed graft func-
tion and maintenance immunosuppressive regimens, etc.
Many of such di¡erences in fact dictated the choice of
induction agents. Although appropriate statistical ap-
proaches were utilized, certain bias and/or confounding
cannot be completely excluded. Second, because the DNA
viremia determination was ordered by individual physi-
cians based on clinical suspicion, it may have under diag-
nosed asymptomatic cases of CMV infection, particularly
if patients did not get induction and were doing well.
Finally, a lower dose of VGCVwas used for prophylaxis as
dictated by the institutional protocol, which might have
resulted in higher incidence of CMV infection in rATG-
treated patients. However, a recent study did show that
VGCV 450 mg daily provided similar drug exposure com-
pared with oral ganciclovir at 1000 mg 3 times daily in kid-
ney transplant patients, a dose similarly e¡ective for CMV
prophylaxis (2, 36, 37 ).
In conclusion, our study demonstrated elevated inci-
dence of late occurrence of CMV infection with the use of
rATG in D 1 /R kidney and/or pancreas transplant pa-
tients following completion of universal prophylaxis. As
both early and late occurrence of CMV infection is a risk
factor for allograft loss and mortality, novel strategies are
urgently needed to reduce such risk in this high-risk group
of SOT patients receiving modern immunosuppressive
regimens.
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